... Health Sciences Center San Antonio, who was not involved with the study. ... Biotechnology, TerSera, and Menarini. Primary Source. San Antonio Breast ...
News
- Less-Frequent Surveillance Mammo Feasible in Older Breast Cancer Survivors
- Dato-DXd Deemed New Treatment Option for HR+, HER2- Advanced Breast Cancer
... San Antonio Breast Cancer Symposium 2023. Researchers found that Dato ... Some study authors declared affiliations with biotech, pharmaceutical, and/or ...
- Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast ...
... San Antonio Breast Cancer Symposium (SABCS). Information on the ... Intensity Therapeutics is a late-stage biotechnology company that applies novel ...
- Genentech's Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival ... - BioSpace
Full data are being presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium on Friday, December 8. Kadcyla is approved ...
- Pregnancy After Breast Cancer Treatment Is Not Contraindicated in BRCA Carriers
... San Antonio Breast Cancer Symposium 2023. The study results provide ... Disclosures: Some study authors declared affiliations with biotech, ...